Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Kerr

Showing results (21-30 of 111) with videos related to

Pageof 12
Sort By:
Critical Reviews in Oncology/Hematology|November 5, 2002
Ras as a target in cancer therapyRachel S Midgley, David J Kerr
Nature Reviews. Clinical Oncology|March 10, 2011
Targeted therapies: bevacizumab--has it reached its final resting place?David J Kerr, Annie M Young
Rare Tumors|December 9, 2010
Malignant peritoneal mesothelioma. Is there a new treatment?Kakil Ibrahim Rasul, David J Kerr
Nature Reviews. Clinical Oncology|August 27, 2009
Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLCKakil Ibrahim Rasul, David J Kerr
Expert Review of Anticancer Therapy|February 25, 2003
Immunotherapy for colorectal cancerRachel S Midgley, David J Kerr
Lancet (London, England)|June 25, 2022
The UK benefits from a truly National Health ServiceEddie Barnes, Gordon Brown, David J Kerr
Acta Oncologica (Stockholm, Sweden)|August 6, 2003
Colorectal cancerShibani Nicum, Rachel Midgley, David J Kerr
The Lancet. Oncology|November 8, 2016
Is sidedness prognostically important across all stages of colorectal cancer?David J Kerr, Enric Domingo, Rachel Kerr
Nature Reviews. Clinical Oncology|August 25, 2011
Predictive biomarkers: a paradigm shift towards personalized cancer medicineNicholas B La Thangue, David J Kerr
Globalization and Health|June 15, 2014
Health diplomacy: a new approach to the Muslim world?Mehrunisha Suleman, Raghib Ali, David J Kerr
Pageof 12

Showing results (21-30 of 111) with videos related to

Sort By:
Pageof 12
Critical Reviews in Oncology/Hematology|November 5, 2002
Ras as a target in cancer therapyRachel S Midgley, David J Kerr
Nature Reviews. Clinical Oncology|March 10, 2011
Targeted therapies: bevacizumab--has it reached its final resting place?David J Kerr, Annie M Young
Rare Tumors|December 9, 2010
Malignant peritoneal mesothelioma. Is there a new treatment?Kakil Ibrahim Rasul, David J Kerr
Nature Reviews. Clinical Oncology|August 27, 2009
Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLCKakil Ibrahim Rasul, David J Kerr
Expert Review of Anticancer Therapy|February 25, 2003
Immunotherapy for colorectal cancerRachel S Midgley, David J Kerr
Lancet (London, England)|June 25, 2022
The UK benefits from a truly National Health ServiceEddie Barnes, Gordon Brown, David J Kerr
Acta Oncologica (Stockholm, Sweden)|August 6, 2003
Colorectal cancerShibani Nicum, Rachel Midgley, David J Kerr
The Lancet. Oncology|November 8, 2016
Is sidedness prognostically important across all stages of colorectal cancer?David J Kerr, Enric Domingo, Rachel Kerr
Nature Reviews. Clinical Oncology|August 25, 2011
Predictive biomarkers: a paradigm shift towards personalized cancer medicineNicholas B La Thangue, David J Kerr
Globalization and Health|June 15, 2014
Health diplomacy: a new approach to the Muslim world?Mehrunisha Suleman, Raghib Ali, David J Kerr
Pageof 12